Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Marina Lewin becomes head of sales for Asset Servicing the US for BNY Mellon

Tuesday, October 23, 2012
Opalesque Industry Update - BNY Mellon has named Marina Lewin head of sales for its Asset Servicing business in the Americas. Lewin will report to Samir Pandiri, CEO of Americas Asset Servicing & Alternative Investment Services. She will be based in New York, managing teams in several U.S. cities, as well as Dublin, London and Hong Kong.

In addition to her new role, Lewin will continue to lead global sales for the company’s Alternative Investment Services (AIS) group. BNY Mellon brought together its two investment services businesses – global custody and hedge fund administration – earlier this year.

“Our AIS business has more than doubled its assets under administration the last four years, with Marina a major force behind that growth,” said Pandiri. “As institutional investors continue to make alternatives a larger core of their portfolios, we’ll see a sharing in the kinds of services we can offer clients on both sides. Services like prime custody also point to the growing need among hedge fund managers for wider custodial capabilities.

“Plan sponsors and hedge fund managers alike are dealing with issues around transparency, new regulations, risk management, and operational efficiency. Marina brings strong leadership skills that will help us integrate the solutions we deliver to all our investment services clients and reach new ones as the industry evolves,” Pandiri added.

Lewin has been with BNY Mellon since 2000. Before joining BNY Mellon she was with JPMorgan and Deutsche Bank and has held a variety of roles in the securities industry, including in operations management, product management, and product development. She’s also had extensive experience leading major business integration projects.

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for